Drug Trial Radar · NCT05826353
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
May 11, 2023
Primary completion
Jan 17, 2025
Study completion Oct 24, 2025
Sponsor
- Lead sponsor
- Kowa Research Institute, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
Conditions
- Fuchs Endothelial Corneal Dystrophy
Interventions
RipasudilDrug
K-321 ophthalmic solution
PlaceboDrug
Placebo ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to improvement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeksTime frame: Baseline to Week 12
Locations
43 sites in 6 countries. Site status is shown where the registry gives one.
Keck Hospital of USC
Los Angeles, California
Macy Eye Center
Los Angeles, California
Byers Eye Institute at Stanford
Palo Alto, California
Sacramento Eye Consultants
Sacramento, California
Gorovoy MD Eye Specialists
Fort Myers, Florida
Bascom Palmer Eye Institute
Palm Beach Gardens, Florida
Grene Vision Group-Wichita
Wichita, Kansas
University of Kentucky
Lexington, Kentucky
W Kellogg Eye Center
Ann Arbor, Michigan
Verdier Eye Center
Grand Rapids, Michigan
Vance Thompson Vision - Omaha
Omaha, Nebraska
Eye Associates of New Mexico - Albuquerque - Northside
Albuquerque, New Mexico
NYU Langone Health
New York, New York
Vance Thompson Vision West Fargo
West Fargo, North Dakota
Cincinnati Eye Institute-1945 Cei Dr
Blue Ash, Ohio
University Hospitals Cleveland Medical Center - 11100 Euclid Ave
Cleveland, Ohio
Devers Eye Institute
Portland, Oregon
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Eye Associates
Houston, Texas
R and R Eye Research, LLC.
San Antonio, Texas
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
Dr. Greg Moloney
Vancouver, British Columbia, Canada
Prism Eye Institute - Mississauga-Oakville
Oakville, Ontario, Canada
Precision Cornea Centre
Ottawa, Ontario, Canada
Rigshospitalet Glostrup-Valdemar Hansens Vej 1-23
Glostrup Municipality, Capital, Denmark
Aarhus Universitetshospital
Aarhus N, Central Jutland, Denmark
LMU Klinikum der Universität
München, Germany
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitatsklinkum Erlangen-Ulmenweg 18
Erlangen, Bavaria, Germany
Uniklinik Köln
Cologne, North Rhine-Westphalia, Germany
Universitatsklinikum Dusseldorf
Düsseldorf, North Rhine-Westphalia, Germany
Universität des Saarlandes
Homburg, Saarland, Germany
Oftalvist - Barcelona
Barcelona, Spain
Institut Catala de Retina (ICR)
Barcelona, Spain
Instituto de Microcirugia Ocular
Barcelona, Spain
Hospital Universitario Germans Trias i Pujol
Badalona, Barcelona, Spain
Althaia Xarxa Assistencial Universitaria Manresa
Manresa, Barcelona, Spain
Hospital Arruzafa
Córdoba, Córdoba, Spain
Instituto Oftalmologico Fernandez Vega
Oviedo, Principality of Asturias, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.